Table 5.

Adjusteda ORs (95% CI) for treatment effect of UDCA by concentrations of 25(OH)D, of 1,25(OH)2D, and sex

RecurrenceAdvanced recurrence
WomenMenWomenMen
Vitamin D metaboliten (%) recur UDCA/placeboOR (95% CI)n (%) recur UDCA/placeboOR (95% CI)Percentage of recur UDCA/placeboOR (95% CI)Percentage of recur UDCA/placeboOR (95% CI)
25(OH)D status
Deficient
 <20 ng/mL30 (42.3)/23 (32.9)1.61 (0.80–3.24)28 (45.2)/24 (48.0)0.88 (0.39–1.96)13 (18.6)/7 (10.0)2.21 (0.79–6.15)8 (12.9)/7 (14.0)0.99 (0.29–3.40)
Inadequate
 ≥20 and <30 ng/mL26 (32.9)/33 (44.6)0.65 (0.33–1.29)76 (43.2)/72 (43.9)0.83 (0.53–1.29)8 (10.1)/7 (9.5)0.99 (0.31–3.11)18 (10.3)/22 (13.4)0.77 (0.39–1.53)
Adequate
 ≥30 ng/mL11 (31.4)/16 (33.3)0.81 (0.31–2.17)71 (42.0)/75 (48.7)0.99 (0.64–1.53)6 (17.1)/5 (10.6)1.15 (0.28–4.64)25 (14.8)/31 (20.1)0.70 (0.38–1.31)
Pinteractionb0.150.810.590.93
1,25(OH)2D tertile
Tertile 1
 23.0 ± 4.4 pg/mL33 (42.3)/31 (42.5)1.09 (0.56–2.11)61 (48.0)/56 (49.6)1.01 (0.60–1.70)12 (15.6)/8 (11.0)1.55 (0.57–4.22)19 (15.1)/20 (17.7)1.01 (0.47–2.17)
Tertile 2
 33.6 ± 2.8 pg/mL16 (31.4)/18 (32.7)0.85 (0.36–1.99)60 (42.3)/60 (45.8)0.97 (0.59–1.59)6 (11.8)/5 (9.1)1.39 (0.38–5.12)18 (12.7)/25 (19.1)0.68 (0.34–1.35)
Tertile 3
 47.1 ± 8.4 pg/mL18 (32.1)/23 (35.9)0.81 (0.36–1.86)54 (39.1)/55 (44.4)0.83 (0.51–1.38)9 (16.1)/6 (9.5)1.37 (0.42–4.46)14 (10.1)/15 (12.1)0.82 (0.36–1.85)
Pinteractionb0.820.930.980.44
  • aModels adjusted for age, BMI, and season of blood draw.

  • bPinteraction calculated with a likelihood-ratio test.